Celgene plunges following the drugmaker’s announcement late Thursday that it would halt phase 3 trials of its Crohn’s disease treatment. For more stories and …
source CNBC
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More